Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein Abundance of Hydrolytic Drug Metabolizing Enzymes in Different Tissues and across Species.

Journal of medicinal chemistry·2026
Same author

Characterization of Lysosomal Hydrolases and Transporters and Their Age-Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs.

Clinical pharmacology and therapeutics·2026
Same author

A New Fluorogenic Substrate for CYP1A2 and Its Application in Studying the Effects of Alcohol Exposure on Liver Drug Metabolism.

bioRxiv : the preprint server for biology·2026
Same author

The role of CYP3A-CYP2E1 interactions in activation of CYP3A enzymes by chronic alcohol exposure.

bioRxiv : the preprint server for biology·2026
Same author

Pharmacogenetic hSLCO1B1*14-Guided Dosing of Methotrexate in Transgenic Arthritic Mice Normalizes Exposure and Response.

Clinical and translational science·2025
Same author

Confounding Effect of Hepatic Carboxylesterase 1 (CES1) Variability on Clopidogrel Oxidation.

Molecular pharmaceutics·2025
Same journal

Correction to "Physicians' Perceptions of Prescribing in Pregnancy and Package Inserts: A Survey of General and Hub Hospitals in Japan".

Clinical and translational science·2026
Same journal

Development of Core Competencies in Clinical Data Science Graduate Education: A Follow-On Tutorial to From Clinical Data Management to Clinical Data Science: Time for a New Educational Model.

Clinical and translational science·2026
Same journal

Population Pharmacokinetic, Exposure-Response Efficacy and Safety Analyses of Favezelimab in Patients With Solid Tumors.

Clinical and translational science·2026
Same journal

Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies.

Clinical and translational science·2026
Same journal

Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study.

Clinical and translational science·2026
Same journal

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.

Clinical and translational science·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Predicting Pharmacokinetic Variability and Drug Interaction Risk Using Omics-Based Biomarkers.

Bhagwat Prasad1

  • 1Division of Translation and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Clinical and Translational Science
|May 7, 2026
PubMed
Summary
This summary is machine-generated.

Understanding drug variability is key for precision dosing. Phenotypic biomarkers offer a proactive approach to predict drug exposure and interactions, improving individualized medicine beyond genetics.

Related Experiment Videos

Last Updated: May 8, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

Area of Science:

  • Pharmacology
  • Precision Medicine
  • Biomarker Discovery

Background:

  • Interindividual variability in drug pharmacokinetics and drug-drug interactions hinders precision dosing, especially for narrow therapeutic index drugs.
  • While genetics play a role, dynamic factors like physiology, disease, age, diet, microbiome, and medications significantly contribute to this variability.
  • Current methods offer limited retrospective insights into drug behavior.

Purpose of the Study:

  • To introduce phenotypic biomarkers as a proactive strategy for quantifying drug variability.
  • To demonstrate the potential of biomarkers in improving drug exposure prediction and assessing interaction risks.
  • To advance individualized dosing strategies beyond traditional pharmacogenomic approaches.

Main Methods:

  • Utilizing emerging phenotypic biomarkers.
  • Quantifying interindividual variability in drug pharmacokinetics.
  • Assessing susceptibility to drug-drug interactions.

Main Results:

  • Phenotypic biomarkers provide a mechanism-based approach to understand drug variability.
  • These biomarkers enable proactive risk assessment for drug interactions.
  • The strategy supports individualized dosing tailored to dynamic patient factors.

Conclusions:

  • Phenotypic biomarkers represent a significant advancement in precision dosing.
  • They offer a proactive, mechanism-based method to manage drug variability and interactions.
  • This approach moves beyond pharmacogenomics for more personalized therapeutic strategies.